GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...

It is tailored to patients being treated with Lilly's oncology drugs – which ... than 30 DiGAs that have approved for use by the BfArM medical regulator and are covered by the national GKV ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Lilly in August began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed ...

Medical industry giants Eli Lilly and Merck will collaborate with Purdue through a new institute, which aims to advance ...

surpassing the Medical sector's loss of 6.22% and falling behind the S&P 500's loss of 1.7%. Investors will be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure.

Pete Yonkman, president of Cook Group and Cook Medical, was among the speakers Monday at the official launch of the new ...

outpacing the Medical sector's loss of 5.64% and lagging the S&P 500's loss of 0.36% in that time. Market participants will be closely following the financial results of Eli Lilly in its upcoming ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease, a type of chronic inflammatory bowel disease.

Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer. The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he ...